Research
Melanoma protein patterns help predict immunotherapy response, survival
The Brief
- Two new University of Pittsburgh studies report that protein patterns in melanoma tumors can predict how patients respond to immunotherapy.
- The same protein patterns can be used to find promising biomarkers and drug targets, according to the researchers.
- The report also links the patterns to survival outcomes in melanoma patients.
Why it matters
If protein signatures reliably predict immunotherapy response, they could help clinicians choose treatments and guide the search for new drug targets in melanoma.
Who’s affected
- melanoma patients and oncologists
- cancer biomarker and drug discovery researchers
Protein patterns in melanoma tumors can predict how patients respond to immunotherapy and can be used to find promising biomarkers and drug targets, according to two new University of Pittsburgh studies.